A 64-year-old nonsmoking woman visited our hospital on April 26, 2019 for further treatment because she could not tolerate the side effects of previous chemotherapy for lung adenocarcinoma, including myelosuppression and cardiac and renal insufficiency. Chest computed tomography (CT) showed bone metastases in the thoracolumbar spine and bilateral local ribs, nodules in both lungs, and pericardial and left pleural effusion. On September 10, 2014, the patient went to a local hospital because of sudden glossolalia with right lower limb numbness, and was diagnosed with stage IIIA lung adenocarcinoma, and then she underwent resection of the upper lobe on September 24, 2014. The patient received pemetrexed combined with carboplatin for four cycles of chemotherapy. In November 2015, the disease progressed. The patient was given paclitaxel plus cisplatin combined with bevacizumab for six cycles from November 11, 2015 to March 11, 2016. From April 1, 2016 to April 26, 2019, the patient received pemetrexed combined with bevacizumab, and his condition remained stable. After the last cycle of treatment with pemetrexed plus bevacizumab, chest CT showed bone metastases in the thoracolumbar spine and bilateral local ribs, nodules in both lungs, and pericardial and left pleural effusion. The previous pathological diagnosis was lung adenocarcinoma. After the last cycle of treatment with pemetrexed plus bevacizumab, CT showed bone metastases in the thoracolumbar spine and bilateral local ribs, nodules in both lungs, and pericardial and left pleural effusion.